We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Advanced Staining Solution to Accelerate Diagnostic Productivity for Mid-Sized and Large Labs

By LabMedica International staff writers
Posted on 20 Apr 2023
Print article
Image: Powered by Universal Access, BOND-PRIME enables labs to seamlessly adapt to any incoming workflows (Photo courtesy of Leica)
Image: Powered by Universal Access, BOND-PRIME enables labs to seamlessly adapt to any incoming workflows (Photo courtesy of Leica)

A more advanced and faster staining solution enables single or STAT slides to be processed in just one hour, allowing pathologists to quickly provide diagnoses, which is crucial for patients requiring urgent diagnostic decisions. This solution reduces the average turnaround time (TAT) for immunohistochemistry (IHC) slides to approximately 90 minutes and ensures 100% instrument utilization without constant supervision.

Leica Biosystems (Nussloch, Germany) has announced the European launch of the BOND-PRIME advanced staining solution, which seamlessly adapts and optimizes workflow to stain slides as required, without leaving any slide staining position unused. It features 70 open-access reagent positions and a total on-board capacity of 72 slides. Besides its adaptability and speed, the platform incorporates innovative technology to further improve the staining quality available to laboratories. This results in consistently sharp, clean stains that are gentle on sample tissue and exhibit minimal carry-over. Leica has introduced Active Reagent Control (ARC) to enable highly controlled reagent application and incubation. BOND-PRIME is now accessible for in vitro diagnostic use in specific countries within the EMEA regions, as well as the United States, Canada, Australia, and New Zealand.

“In today’s fast-paced healthcare environment, adaptability is essential to ensure that slides are processed in a timely manner, without compromising on quality,” explained Colin White, Senior Vice President of Advanced Staining, and Imaging. “BOND-PRIME is a generation ahead. It enables labs to achieve a high-speed, continuous workflow, an average single slide TAT of 90 minutes, no downtime and minimal need for manual intervention. The impact on quality and productivity is truly impressive.”

“We have a history of innovation that addresses specific customer needs,” said Gustavo Perez-Fernandez, President at Leica Biosystems. “The BOND-PRIME staining solution presents a quantifiable benefit to mid-sized and large laboratories in terms of both quality and greater efficiency. STAT cases can be processed quickly and efficiently, without holding back the validation of more routine cases. By streamlining workflow, the use of BOND-PRIME ensures that fewer cases overall are left pending.”

Related Links:
Leica Biosystems

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.